Director/PDMR's Dealing

RNS Number : 7386E
Oncimmune Holdings PLC
02 March 2020
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Director/PDMR's Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, announces the following dealing in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by Carsten Schroeder, PDMR and Non-Executive Director. The Company was notified on 28 February 2020.

 

PDMR

Date of purchase

Number of shares purchased

Purchase price

Total shares held

% ISC held following
purchase

Carsten Schroeder

28 February 2020

9,000

£0.541

9,000

0.00014%

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Carsten Schroeder

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Oncimmune Holdings plc

b)

 

LEI

 

 

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

 

 

Purchase of shares

c)

 

Price(s) and volume(s)







Price

Volume




0.541 GBP

9,000







d)

 

Aggregated information




- Aggregated volume

Same as above



- Price




e)

 

Date of the transaction

 

 

28 February 2020

f)

 

Place of the transaction

 

 

London stock exchange, AIM

 

For further information:

 

Oncimmune Holdings plc

Andrew Stewart, General Counsel and Company Secretary

contact@oncimmune.com  

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHSSDFIEESSEDD
UK 100

Latest directors dealings